Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 5:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Schizophrenic Disorders Clear all
Terminated Phase 2 Interventional

Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia

NCT05182476
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Luvadaxistat
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 50 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
33
States / cities
Phoenix, Arizona • Bentonville, Arkansas • Bryant, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Sep 26, 2026, 5:00 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Cannabinoids, Learning, and Memory

NCT02407808
View directory record Official record
Conditions
Cannabis, Psychotic Disorders
Interventions
THC, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 26, 2026, 5:00 AM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of Risperidone Implants

NCT02773576
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone implant
Drug
Lead sponsor
Braeburn Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Garden Grove, California
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Sep 26, 2026, 5:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Randomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset Schizophrenia

NCT01773239
View directory record Official record
Conditions
Schizophrenia
Interventions
TARA computer-based exercises
Behavioral
Lead sponsor
Posit Science Corporation
Industry
Eligibility
18 Years to 35 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Sep 26, 2026, 5:00 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Reliability and Validity of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)

NCT00579267
View directory record Official record
Conditions
Major Depression, Mania, Anxiety Disorders, Psychotic Disorder, Alcohol Dependence, Drug Dependence, Eating Disorders, Suicidality, Dysthymia, ADHD, Tourettes Disorder, Conduct Disorder, Oppositional Defiant Disorder, Pervasive Developmental Disorder
Interventions
MINI-KID
Other
Lead sponsor
University of South Florida
Other
Eligibility
6 Years to 17 Years
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 15, 2009 · Synced Sep 26, 2026, 5:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Targeting Cerebellum to Treat Psychosis: a Transcranial Magnetic Stimulation (TMS) Study

NCT02642029
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder I
Interventions
Excitatory TMS, Inhibitory TMS, Sham TMS
Device
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
2
States / cities
Belmont, Massachusetts • Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Sep 26, 2026, 5:00 AM EDT
Suspended Phase 1Phase 2 Interventional

D-serine AudRem: R33 Phase

NCT05046353
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder
Interventions
D-serine, Placebo
Drug · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 26, 2026, 5:00 AM EDT
Completed Phase 2 Interventional Results available

Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia

NCT01012167
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin, Galantamine, Placebo-Oxytocin, Placebo-Galantamine
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
6
States / cities
Baltimore, Maryland • Catonsville, Maryland • Dundalk, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Sep 26, 2026, 5:00 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

NCT06887192
View directory record Official record
Conditions
Psychosis Associated With Alzheimer's Disease
Interventions
ML-007C-MA, Placebo
Drug
Lead sponsor
MapLight Therapeutics
Industry
Eligibility
55 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
34
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 26, 2026, 5:00 AM EDT
Completed Phase 3 Interventional

Immediate Release (IR) to Sustained Release (SR) Switching Study: Study of Switching From IR Seroquel to SR Seroquel in Outpatients With Schizophrenia

NCT00206128
View directory record Official record
Conditions
Schizophrenia
Interventions
Seroquel SR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
18
States / cities
Birmingham, Alabama • Anaheim, California • Cerritos, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Sep 26, 2026, 5:00 AM EDT
Not listed Not applicable Interventional

Comparing Cognitive Remediation Approaches for Schizophrenia

NCT04123223
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Cognitive Remediation, Computer Games
Behavioral
Lead sponsor
Wesleyan University
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Hartford, Connecticut • Middletown, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Sep 26, 2026, 5:00 AM EDT
Completed Phase 1 Interventional

Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants

NCT02087579
View directory record Official record
Conditions
Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
Interventions
Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation, Paliperidone, LAI, Quetiapine, oral formulation, Risperidone, oral formulation, Risperidone, LAI
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
6
States / cities
Garden Grove, California • Kissimmee, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Sep 26, 2026, 5:00 AM EDT
Completed Phase 3 Interventional Results available

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia

NCT04268303
View directory record Official record
Conditions
Agitation, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Schizophreniform Disorders
Interventions
Sublingual film containing dexmedetomidine (BXCL501), Placebo Film
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
15
States / cities
Little Rock, Arkansas • Cerritos, California • Culver City, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 26, 2026, 5:00 AM EDT
Completed Phase 2Phase 3 Interventional

Galantamine for Cognitive Deficits in Schizophrenia

NCT00463879
View directory record Official record
Conditions
Schizophrenia
Interventions
Galantamine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 11, 2007 · Synced Sep 26, 2026, 5:00 AM EDT
Completed Phase 3 Interventional

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

NCT01714661
View directory record Official record
Conditions
Schizophrenia, Impaired Cognition
Interventions
EVP-6124, Placebo
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
38
States / cities
Tucson, Arizona • Anaheim, California • Bellflower, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Sep 26, 2026, 5:00 AM EDT
Completed No phase listed Observational

Adherence in Patients Admitted to a Psychiatric Unit for Acute Psychosis: an Analysis of Serum Levels of Antipsychotics.

NCT01786369
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Sep 26, 2026, 5:00 AM EDT
Completed Phase 2 Interventional Results available

An Active-Controlled Early Phase Study of Elpipodect (MK-8189) in Adults With Schizophrenia (MK-8189-005)

NCT03055338
View directory record Official record
Conditions
Schizophrenia, Acute Episode
Interventions
Elpipodect, Risperidone, Placebo matching MK-8189, Placebo matching risperidone
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
28
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Bellflower, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 26, 2026, 5:00 AM EDT
Not listed Phase 4 Interventional

DIMES - DIgital MEdicine Study for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole

NCT03881449
View directory record Official record
Conditions
Schizophrenia, Major Depressive Disorder, Bi-Polar Disorder, Schizo Affective Disorder
Interventions
ABILIFY MYCITE
Combination Product
Lead sponsor
Durham VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Sep 26, 2026, 5:00 AM EDT
Recruiting Not applicable Interventional

BRAVE Program to Improve Safety and Reduce Violence Risk in Early Psychosis

NCT07417904
View directory record Official record
Conditions
Violence Risk, Early Psychosis
Interventions
BRAVE (Behavioral Response Against Violence Engagement), Treatment As Usual (TAU)
Behavioral · Other
Lead sponsor
Howard University
Other
Eligibility
16 Years to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 26, 2026, 5:00 AM EDT
Completed Phase 2 Interventional Results available

Study of the Safety, Tolerability, and Pharmacokinetics of Once Weekly Zicronapine in Patients With Schizophrenia

NCT01377233
View directory record Official record
Conditions
Schizophrenia
Interventions
Zicronapine open-label lead-in 10 mg daily, Zicronapine 10 mg daily, Zicronapine 20 mg once weekly, Zicronapine 30 mg once weekly, Zicronapine 45 mg once weekly
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
4
States / cities
Garden Grove, California • National City, California • San Diego, California + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Sep 26, 2026, 5:00 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ascertaining Diagnosis Classification With Elicited Speech

NCT05601063
View directory record Official record
Conditions
Schizophrenia Spectrum and Other Psychotic Disorders, Bipolar and Related Disorders, Depressive Disorder, Anxiety Disorders, Personality Disorders, Attention Deficit Hyperactivity Disorder
Interventions
Winterlight Speech Assessment
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
14 Years to 50 Years
Enrollment
255 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Sep 26, 2026, 5:00 AM EDT
Completed Phase 1 Interventional

Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia

NCT01394471
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Intranasal Oxytocin Spray
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Sep 26, 2026, 5:00 AM EDT
Completed Phase 2 Interventional Results available

A Study of ALKS 3831 in Adults With Schizophrenia

NCT01903837
View directory record Official record
Conditions
Schizophrenia
Interventions
Samidorphan (Low Dose), Samidorphan (Medium Dose), Samidorphan (High Dose), Placebo, Olanzapine
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
50
States / cities
Little Rock, Arkansas • Anaheim, California • Costa Mesa, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Sep 26, 2026, 5:00 AM EDT
Withdrawn Phase 2 Interventional

Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder

NCT01981811
View directory record Official record
Conditions
Bipolar 1 Disorder, Schizophrenia, Mental Disorder, Nervous System Diseases
Interventions
Aripiprazole, Ingestible Event Marker (IEM)
Drug · Device
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
12
States / cities
Cerritos, California • Garden Grove, California • Long Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Sep 26, 2026, 5:00 AM EDT